{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:27:16Z","timestamp":1792211236595,"version":"4.4.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamaophthalmol.2021.6284","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:02:41Z","timestamp":1645095761000},"page":"328","source":"Crossref","is-referenced-by-count":73,"title":["Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease"],"prefix":"10.1001","volume":"140","author":[{"given":"Raymond S.","family":"Douglas","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Dailey","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem S.","family":"Subramanian","sequence":"additional","affiliation":[{"name":"University of Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barbesino","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Ugradar","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Batten","sequence":"additional","affiliation":[{"name":"EVERSANA, Sydney, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana A.","family":"Qadeer","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cameron","sequence":"additional","affiliation":[{"name":"EVERSANA, Sydney, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"eoi210090r1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy.","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"eoi210090r2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/IOP.0000000000001292","article-title":"Bony orbital volume expansion in thyroid eye disease.","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"eoi210090r3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 Orbitopathy (GO) and relationship with thyroid disease.","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"eoi210090r4","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy.","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"eoi210090r5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13044-020-00086-7","article-title":"Teprotumumab: a disease modifying treatment for Graves\u2019 orbitopathy.","volume":"13","author":"Ting","year":"2020","journal-title":"Thyroid Res"},{"issue":"8","key":"eoi210090r6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40618-017-0717-8","article-title":"Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves\u2019 orbitopathy?","volume":"40","author":"Piantanida","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"18","key":"eoi210090r7","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy.","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"eoi210090r8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease.","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi210090r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy.","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"2","key":"eoi210090r10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"eoi210090r11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"12","key":"eoi210090r12","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy.","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"eoi210090r13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"eoi210090r14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy.","volume":"61","author":"Aktaran","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"2","key":"eoi210090r15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","article-title":"Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves\u2019 ophthalmopathy: a prospective, randomized controlled trial.","volume":"64","author":"He","year":"2017","journal-title":"Endocr J"},{"issue":"9","key":"eoi210090r16","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy.","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"eoi210090r17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/etm","article-title":"Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: a single center prospective randomized trial.","volume":"20","author":"Mu","year":"2020","journal-title":"Exp Ther Med"},{"issue":"6","key":"eoi210090r18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves\u2019 ophthalmopathy.","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"eoi210090r19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.v74.11","article-title":"Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves\u2019 orbitopathy.","volume":"74","author":"Beleslin","year":"2020","journal-title":"Int J Clin Pract"},{"issue":"3","key":"eoi210090r20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40618-020-01322-5","article-title":"Changes in ocular biomechanics after treatment for active Graves\u2019 orbitopathy.","volume":"44","author":"Li","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"eoi210090r21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/bjophthalmol-2014-306463","article-title":"Smoking was associated with poor response to intravenous steroids therapy in Graves\u2019 ophthalmopathy.","volume":"99","author":"Xing","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"eoi210090r22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40618-019-01174-8","article-title":"Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.","volume":"43","author":"Xu","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"eoi210090r23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/IOP.0000000000000036","article-title":"What is the aim of immunosuppressive treatment in patients with Graves\u2019 orbitopathy?","volume":"30","author":"Yang","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"eoi210090r25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"eoi210090r26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.autrev.2017.12.012","article-title":"Quality of life and neuropsychiatric disorders in patients with Graves\u2019 orbitopathy: current concepts.","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"17","key":"eoi210090r27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3238\/arztebl.2009.0283","article-title":"Quality of life and occupational disability in endocrine orbitopathy.","volume":"106","author":"Ponto","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"eoi210090r28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"eoi210090r29","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4845894","article-title":"Corticosteroids for Graves\u2019 ophthalmopathy: systematic review and meta-analysis.","volume":"2018","author":"Tu","year":"2018","journal-title":"Biomed Res Int"},{"issue":"2","key":"eoi210090r30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1155\/2018\/4845894","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study.","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"eoi210090r31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.18240\/ijo","article-title":"Intravenous glucocorticoids therapy in the treatment of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis.","volume":"12","author":"Zhao","year":"2019","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"eoi210090r32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study.","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"eoi210090r33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-13-0611","article-title":"The therapeutic outcome to intravenous steroid therapy for active Graves\u2019 orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.","volume":"170","author":"Vannucchi","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"eoi210090r34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.","volume":"87","author":"Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"eoi210090r24","unstructured":"Phillippo? D, Ades? T, Dias? S, Palmer? S, Abrams? KR, Welton? N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Accessed January 4, 2022. https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2788918\/jamaophthalmology_douglas_2022_oi_210090_1649949526.74687.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:27:13Z","timestamp":1650540433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2788918"}},"subtitle":["A Meta-analysis and Matching-Adjusted Indirect Comparison"],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6284","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741670124.793597388","asserted-by":"object"}]},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}